



**META HEALTH LIMITED**

(Incorporated in the Republic of Singapore)  
(Company Registration No.: 198804700N)

---

**PROFIT GUIDANCE FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022**

---

The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce that, following a preliminary review of the Group’s unaudited consolidated financial results for the financial year ended 31 December 2022 (“**FY2022**”), the Group is expected to report a net loss for FY2022 (“**Net Loss**”).

The Net Loss was mainly due to the decrease in sales revenue from the Group’s Metal business attributable to the following:

- (i) lockdown in China due to the COVID-19 pandemic that severely impacted the sales in China during FY2022;
- (ii) continued shortage of IC chips globally affecting the Group’s customers’ demands; and
- (iii) high inflation, interest rate environment and the on-going Sino-US trade war.

The Group is in the process of finalising its unaudited consolidated financial results for FY2022. Further details of the Group’s financial performance for FY2022 will be disclosed when the Company announces the Group’s unaudited consolidated financial results for FY2022 on or before 1 March 2023.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s securities and are advised to read this announcement and any further announcements by the Company carefully. When in doubt, shareholders and potential investors of the Company are advised to seek independent advice from their professional advisor before trading or making any investment decision on the Company’s securities.

**By Order of the Board**

Dr Bernard Ng Kee Huat  
Executive Chairman and Group Chief Executive Officer  
31 January 2023

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “**Sponsor**”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalyst.*

*This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.*